Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 6/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 5/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329299 | 0.89 | EPHB4 (0.51) | EPHB4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4323890 | 0.87 | EPHB4 (0.48) | EPHB4KDRFLT1MAPK9MAPK10 | |
| SCHEMBL4330819 | 0.85 | EPHB4 (0.52) | EPHB4MAPTMEN1RAB9AKMT2A | |
| SCHEMBL4331441 | 0.83 | BLM (0.51) | EPHB4KDRFLT1BLMWRN | |
| SCHEMBL4329250 | 0.83 | BLM (0.57) | EPHB4MAPTMEN1KMT2AKDR | |
| SCHEMBL4323342 | 0.83 | RAF1 (0.54) | EPHB4MAPTRAB9AKDREGFR | |
| SCHEMBL4324266 | 0.83 | EPHB4 (0.43) | EPHB4MAPTKDREGFRFGFR1 | |
| SCHEMBL4320037 | 0.83 | BLM (0.52) | EPHB4KDRFGFR1FLT1TRPV1 | |
| SCHEMBL4324307 | 0.82 | BLM (0.57) | EPHB4MEN1KMT2AKDREGFR | |
| SCHEMBL4336976 | 0.82 | KDR (0.55) | EPHB4KDREGFRFGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858877-B1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2014-03-12 | — | — | EP | claimed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | claimed |
| EP-1858877-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | claimed |
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076592-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| EP-1858877-B1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1858877-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076592-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | UCK2, AXL, CHUK | EPHB4 2943/4885MAPT 1868/4885MEN1 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.